On November 12, 2026, Arbutus Biopharma Corporation posted an updated corporate presentation on its website at www.arbutusbio.com. A copy of the presentation is filed herewith as Exhibit 99.1 and is incorporated by reference herein.
|
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease, specifically developing therapeutics for chronic hepatitis B (cHBV). The company’s pipeline includes imdusiran (AB-729), a proprietary GalNAc-conjugated, subcutaneously-delivered RNAi therapeutic, and AB-101, a proprietary oral PD-L1 inhibitor. Arbutus also holds intellectual property in lipid nanoparticle (LNP) technology, which is the subject of ongoing patent litigation against Pfizer and BioNTech and a settled agreement with Moderna. Through an exclusive license with Genevant Sciences GmbH, Arbutus leverages its LNP technology platform, while its primary business focus remains the advancement of its cHBV development programs. The company targets patients with chronic hepatitis B infection, aiming to achieve functional cure through combination therapies that suppress viral replication and boost immune response. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Biotechnology | Homepage arbutusbio.com |
| Sector Healthcare | IR page investor.arbutusbio.com | |
|
Tags
hepatitis b, rna interference, lipid nanoparticles, pd-l1 inhibitors, infectious disease, clinical stage, imdusiran, AB-729, AB-101, Genevant Sciences GmbH, Genevant
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 952.539M |
| Market cap (USD) | $ 952.539M |
| P/E | 4.23 |
| PEG | — |
| P/BV | 11.11 |
| P/S | 5.25 |
| P/OCF | 4.31 |
| P/FCF | -24.03 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -38.5% |
| ROI | -57.0% |
| ROIC | -48.7% |
| Profit margin | -237.9% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 76 |
| Quality score | -41.2% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.083M | 6.171M | 18.141M | 39.019M | 10.988M | 6.914M | 6.011M | 5.945M | 10.7M | 1.491M | 24.873M | 14.953M | 15.464M | 14.171M | 16.991M | 20.55M | 13.141M |
| Net profit | -33.501M | -69.92M | -72.849M | -69.456M | -76.247M | -63.745M | -153.723M | -57.06M | -84.413M | -384.164M | -61.121M | -38.837M | -14.064M | 29.926M | -10.142M | -11.948M | -7.969M |
| Free cash flow | -39.637M | -65.032M | -86.944M | -35.868M | -68.341M | -51.67M | -71.595M | -69.004M | -55.904M | -61.881M | -57.072M | -13.477M | -7.464M | 33.232M | -7.898M | -11.624M | — |
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 4.81 | 3.27 | 2.5 | 2.33 | 3.89 | 3.55 | 2.78 | 3.83 | 5.05 | 2.45 | 4.45 | — | — | — | — | — | — |
| Price performance 12m | 0.47 | 0.31 | 0.07 | -0.4 | 0.1 | 0.28 | -0.27 | -0.24 | 1.06 | -0.45 | — | — | — | — | — | — | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (USD) | 273,000 | 402,000 | 1.43M | 1.2M | 1.31M | 899,000 | 1.35M | 1.78M | 2.41M | 1.45M |
| ↳ YoY growth | -72.9% | +47.3% | +256.0% | -15.9% | +9.0% | -31.5% | +50.4% | +31.4% | +35.6% | -39.9% |
| ↳ 5y CAGR | +65.1% | -8.7% | +5.4% | +26.9% | +27.5% | +4.4% | +14.9% | +2.0% | ||
| Lease liabilities (USD) | — | — | 0.00 | 3.36M | 2.98M | 2.61M | 2.19M | 1.77M | 1.29M | 746,000 |
| Cash and deposits (USD) | 23.4M | 54.3M | 36.9M | 31.8M | 52.3M | 109M | 30.8M | 26.3M | 36.3M | 18M |
| Intangible assets (USD) | 99.4M | 58.6M | 43.8M | 0.00 | — | — | — | — | — | — |
| Right-of-use assets (USD) | — | — | 0.00 | 2.74M | 2.41M | 2.09M | 1.74M | 1.42M | 1.05M | 0.00 |
| Cash flow detail | ||||||||||
| Operating cash flow (USD) | -57.9M | -48.6M | -67.9M | -71M | -51.4M | -67.5M | -35.4M | -85.9M | -64.9M | -39.6M |
| Purchases of property, plant and equipment (USD) | -4M | -7.26M | -1.14M | -589,000 | -229,000 | -809,000 | -512,000 | -1.01M | -182,000 | 0.00 |
| Change in receivables (cash effect) (USD) | 735,000 | -129,000 | -1.03M | 227,000 | -108,000 | 413,000 | -453,000 | -424,000 | -633,000 | 1.38M |
| Change in payables (cash effect) (USD) | 26,000 | 736,000 | -1.27M | -2.41M | 1.67M | 1.91M | 5.22M | -5.76M | -2.71M | -2.11M |
| Interest paid (cash effect) (USD) | — | — | -104,000 | 0.00 | — | — | — | — | — | — |
| Share-based compensation (USD) | 39.2M | 15.1M | 6.24M | 6.8M | 6.16M | 6.42M | 7.18M | 9.3M | 8.99M | 6.95M |
| Operating cash flow before change in receivables (USD) | -58.6M | -48.5M | -66.8M | -71.2M | -51.3M | -67.9M | -34.9M | -85.5M | -64.2M | -41M |
| Free cash flow (OCF - PPE - intangibles) (USD) | -61.9M | -55.9M | -69M | -71.6M | -51.7M | -68.3M | -35.9M | -86.9M | -65M | -39.6M |
| Income detail | ||||||||||
| Research and development expense (USD) | 61.3M | 62.7M | 57.9M | 57.6M | 47.5M | 65.5M | 84.4M | 73.7M | 54M | 25.2M |
| ↳ 5y CAGR | +22.0% | +8.3% | -1.6% | +1.4% | +6.1% | +4.9% | -1.3% | -11.9% | ||
| Total comprehensive income (USD) | -384M | -84.4M | -57M | -154M | -63.7M | -76.4M | -71.6M | -70.8M | -69.6M | -33.5M |
| Comprehensive income to owners (USD) | -384M | -84.4M | -57M | -154M | -63.7M | -76.4M | -71.6M | -70.8M | -69.6M | -33.5M |
| Reported | Mar 22, 2017 | Mar 16, 2018 | Mar 5, 2020 | Mar 5, 2020 | Mar 4, 2021 | Mar 3, 2022 | Mar 2, 2023 | Mar 5, 2024 | Mar 27, 2025 | Mar 23, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
Maintained strong financial position with cash, cash equivalents and marketable securities of $337.5M as of September 30, 2026, including receipt of cash dividend of $67.3M from Genevant
Successfully returned $230M of capital to shareholders via tender offer in early October 2026
Expanded international patent infringement enforcement against Pfizer and BioNTech by filing new lawsuits in Japan and amending a previously filed Canadian lawsuit to add an additional LNP patent
FDA lifted clinical hold on IND application for AB-101, an oral PD-L1 inhibitor
WARMINSTER, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today reported third quarter 2026 financial results and provided a corporate update.
“This has been a busy and productive quarter for the Arbutus team,” said Lindsay Androski, President and CEO of Arbutus. “I would like to congratulate our finance team, which successfully returned a substantial portion of Moderna’s first patent infringement payment to shareholders, and our R&D team, for achieving the lift of the 2023 U.S.
Oct 22, 2026
Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor
WARMINSTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that the Company was notified by the U.S. Food and Drug Administration (“FDA”) that the clinical hold on the Investigational New Drug (“IND”) application for AB-101 has been removed and that the Company may engage in additional clinical development for AB-101 in the United States. Arbutus is evaluating next steps for the continued development of AB-101.
AB-101 is a proprietary oral PD-L1 inhibitor that has the potential to activate patients’ hepatitis B virus (“HBV”)-specific immune response by inhibiting PD-L1. AB-101 has completed a Phase 1a/1b clinical trial (AB-101-001) evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single- and multiple-ascending oral doses in healthy subjects and patients with chronic HBV (“cHBV”) infection. The data from healthy subjects in Parts 1 and 2 and cHBV patients in Part 3 of this clinical trial have shown that AB-101 was generally well-tolerated with evidence of high receptor occupancy in seven cHBV patients and hepatitis B surface antigen decline in two cHBV patients at the 30mg dose.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is currently developing imdusiran (AB-729) and an oral PD-L1 inhibitor (AB-101) for the treatment of cHBV infection. The Company is also consulting closely with and supporting its exclusive licensee, Genevant Sciences, to protect and defend its intellectual property, which is the subject of on-going lawsuits against Pfizer Inc., BioNTech SE, and certain of their affiliates, for use of Arbutus’ patented LNP technology in their COVID-19 vaccines. For more information, visit www.arbutusbio.com.
About AB-101
AB-101 is an oral PD-L1 inhibitor candidate that is designed to allow for controlled checkpoint blockade while minimizing the systemic safety issues typically seen with checkpoint antibody therapies. Immune checkpoints such as PD-1/PD-L1 play an important role in the induction and maintenance of immune tolerance and in T-cell activation, for example against HBV. In Arbutus’ Phase 1a/1b clinical trial, AB-101 was generally well-tolerated with evidence of high receptor occupancy.
About HBV
Hepatitis B is a potentially life-threatening liver infection caused by HBV. HBV can cause chronic infection which leads to a higher risk of death from cirrhosis and liver cancer. cHBV infection represents a significant unmet medical need. The World Health Organization estimates that over 250 million people worldwide suffer from cHBV infection, while other estimates indicate that approximately 2 million people in the United States suffer from cHBV infection. Approximately 1.1 million people die every year from complications related to cHBV infection despite the availability of effective vaccines and current treatment options.
Forward-Looking Statements and Information
This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward-looking information within the meaning of Canadian securities laws (collectively, forward-looking statements). Forward-looking statements in this press release include statements about: the Company’s plans for the development of AB-101; the potential to lead to a functional cure for HBV; the potential for Arbutus’ product candidates to achieve success in clinical trials; and Arbutus’ pipeline and development plans for its cHBV programs.
With respect to the forward-looking statements contained in this press release, Arbutus has made numerous assumptions regarding, among other things: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the continued demand for Arbutus’ assets; and the stability of economic and market conditions. While Arbutus considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause Arbutus’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: ongoing and anticipated clinical trials may be more costly or take longer to complete than anticipated, and may never be initiated or completed, or may not generate results that warrant future development of the tested product candidate; Arbutus may elect to change its strategy regarding its product candidates and clinical development activities; Arbutus may not receive the necessary regulatory approvals for the clinical development of Arbutus’ product candidates; economic and market conditions may worsen; and market shifts may require a change in strategic focus.
A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus’ Annual Report on Form 10-K, Arbutus’ Quarterly Reports on Form 10-Q and Arbutus’ continuous and periodic disclosure filings, which are available at www.sec.gov and at www.sedarplus.ca. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.

Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
Company History
Name and ticker changes, and re-registrations under a new regulatory id. When a ticker stopped being used is not recorded, so former tickers are undated.
| Date | Change | Detail |
|---|---|---|
| Aug 5, 2015 | Renamed | TEKMIRA PHARMACEUTICALS CORP → ARBUTUS BIOPHARMA CORP |
| Mar 31, 2013 | Reporting currency | Its US reports are in USD instead of CAD from this period. Earlier figures are shown in USD, converted at each period end's exchange rate. |
ETFs Holding Arbutus Biopharma Corporation
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| JSML | 0.62% | 521,191 | $ 2.262M | Jul 31, 2026 |
| WCEO | 0.17% | 3,869 | $ 16.791K | Jul 31, 2026 |
| FSEG | 0.05% | 652 | $ 3,129.60 | Jun 30, 2026 |
| RESM | 0.02% | 183 | $ 878.40 | Jun 30, 2026 |
| AVSC | 0.02% | 128,236 | $ 518.073K | Nov 16, 2026 |
| FESM | 0.02% | 237,117 | $ 1.138M | Jun 30, 2026 |
| MSSM | 0.01% | 11,648 | $ 59.172K | Aug 31, 2026 |










